NCT04974047View on ClinicalTrials.gov

Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

April 17, 2023

Study Completion Date

October 25, 2024

Conditions
Resectable Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Tislelizumab

Administered intravenously as specified in the treatment arm.

Trial Locations (8)

200032

Affiliated Zhongshan Hospital of Fudan University, Shanghai

230000

Anhui Provincial Hospital, Hefei

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

350001

Fujian Medical University Union Hospital, Fuzhou

430022

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

610041

West China Hospital, Sichuan University, Chengdu

710038

Tangdu Hospital, Xi'an

050011

The Fourth Hospital of Hebei Medical University, Shijiazhuang

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT04974047 - Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter